These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23396586)

  • 1. scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors.
    Cai Z; Fu T; Nagai Y; Lam L; Yee M; Zhu Z; Zhang H
    Cancer Res; 2013 Apr; 73(8):2619-27. PubMed ID: 23396586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.
    Tang Y; Lou J; Alpaugh RK; Robinson MK; Marks JD; Weiner LM
    J Immunol; 2007 Sep; 179(5):2815-23. PubMed ID: 17709495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity.
    McCall AM; Shahied L; Amoroso AR; Horak EM; Simmons HH; Nielson U; Adams GP; Schier R; Marks JD; Weiner LM
    J Immunol; 2001 May; 166(10):6112-7. PubMed ID: 11342630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.
    Shahied LS; Tang Y; Alpaugh RK; Somer R; Greenspon D; Weiner LM
    J Biol Chem; 2004 Dec; 279(52):53907-14. PubMed ID: 15471859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.
    Mohseni Nodehi S; Repp R; Kellner C; Bräutigam J; Staudinger M; Schub N; Peipp M; Gramatzki M; Humpe A
    PLoS One; 2012; 7(8):e42426. PubMed ID: 22879978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
    McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
    Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg.
    Fuenmayor J; Perez-Vazquez K; Perez-Witzke D; Penichet ML; Montano RF
    Mol Cancer Ther; 2010 Aug; 9(8):2175-85. PubMed ID: 20682652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen.
    Wang B; Yang C; Jin X; Du Q; Wu H; Dall'Acqua W; Mazor Y
    MAbs; 2020; 12(1):1690959. PubMed ID: 31829766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
    Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
    Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
    Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
    Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.
    Brandsma AM; Ten Broeke T; Nederend M; Meulenbroek LA; van Tetering G; Meyer S; Jansen JH; Beltrán Buitrago MA; Nagelkerke SQ; Németh I; Ubink R; Rouwendal G; Lohse S; Valerius T; Leusen JH; Boross P
    Cancer Immunol Res; 2015 Dec; 3(12):1316-24. PubMed ID: 26407589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target Antigen.
    Mazor Y; Yang C; Borrok MJ; Ayriss J; Aherne K; Wu H; Dall'Acqua WF
    PLoS One; 2016; 11(6):e0157788. PubMed ID: 27322177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
    Hristodorov D; Mladenov R; Brehm H; Fischer R; Barth S; Thepen T
    MAbs; 2014; 6(5):1283-9. PubMed ID: 25517313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Pereira NA; Chan KF; Lin PC; Song Z
    MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation of scFv antibody fragments against HER2 and CEA tumor antigens from combinatorial antibody libraries derived from cancer patients.
    Ayat H; Burrone OR; Sadghizadeh M; Jahanzad E; Rastgou N; Moghadasi S; Arbabi M
    Biologicals; 2013 Nov; 41(6):345-54. PubMed ID: 23845693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
    El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.